Home | All trials

[RDF data]
Trial NCT00000231

Resource URI: http://static.linkedct.org/resource/trials/NCT00000231
PropertyValue
linkedct:brief_title Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/8908>
linkedct:condition <http://static.linkedct.org/resource/condition/9249>
linkedct:criteria Please contact site for information.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age N/A
linkedct:eligibility_minimum_age 18 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000231
rdfs:label Trial NCT00000231
linkedct:lastchanged_date August 16, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/149541>
linkedct:nct_id NCT00000231
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Buprenorphine Detoxification With Two Types of Treatment. BBD IV
linkedct:org_study_id NIDA-06969-13
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60820>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000231>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/13480>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14723>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/19100>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/26124>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/26125>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7287>
linkedct:secondary_id R01-06969-13
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date February 1992
linkedct:study_design Treatment
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
rdf:type linkedct:trials
linkedct:verification_date March 1994